Quercetin ameliorates non-alcoholic fatty liver disease (NAFLD) via the promotion of AMPK-mediated hepatic mitophagy.

作者：Peng Cao, Yi Wang, Cong Zhang, Mitchell A. Sullivan, Wen Chen, X. Jing, Huifan Yu, Fei Li, Qu Wang, Zhongshi Zhou, Qi Wang, Wen Tian, Zhenpeng Qiu, Lianxiang Luo · 发表于：Journal of Nutritional Biochemistry · 年份：2023 · DOI：10.1016/j.jnutbio.2023.109414 · 被引用次数：114 · 研究领域：Medicine

BACKGROUND The global incidence of non-alcoholic fatty liver disease (NAFLD) has been surging in recent years, however, no drug is currently approved to treat this disease. PURPOSE Quercetin, a natural flavonoid abundant in plants and fruits, has been reported to alleviate NAFLD, however, the exact molecular mechanism remains unclear. This study aims to further elucidate its potential mechanism of action. METHODS The beneficial effects and the underlying mechanism of quercetin in alleviating NAFLD were explored both in vitro and in vivo, by employing chemical inhibitors of autophagosomes (3-methyladenine, 3-MA), autolysosomes (chloroquine, CQ), AMPK (Compound C, CC) and SIRT1 (selisistat, EX-527). The levels of intracellular lipids, reactive oxygen species, mitochondria function, autophagy and mitophagy were assessed by fluorescent labeling and examined using flow cytometry or confocal microscopy. Key protein expressions of autophagy, mitophagy and inflammation were also determined. RESULTS In vivo, quercetin was shown to dose-dependently effectively alleviate NAFLD, but intraperitoneal injection of 3-MA could block the beneficial effects of quercetin on body weight, liver weight, serum ALT/AST, hepatic ROS and inflammation. In vitro, quercetin could reduce intracellular lipids (Nile Red staining) and ROS/DHE accumulation, which could be also blocked by 3-MA or CQ. Furthermore, we found that CC could abrogate the protective effects of quercetin on lipid and ROS accumula...